Next Article in Journal
Potential Involvement of Peripheral Leptin/STAT3 Signaling in the Effects of Resveratrol and Its Metabolites on Reducing Body Fat Accumulation
Previous Article in Journal
Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid

1
Department of Systems Medicine, University of Rome Tor Vergata, 00173 Rome, Italy
2
Laboratory of Molecular Oncology, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, 00167 Rome, Italy
3
Laboratory of Medicinal Chemistry, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00173 Rome, Italy
4
Urology Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00173 Rome, Italy
*
Author to whom correspondence should be addressed.
Nutrients 2018, 10(11), 1756; https://doi.org/10.3390/nu10111756
Received: 29 October 2018 / Revised: 11 November 2018 / Accepted: 12 November 2018 / Published: 14 November 2018
  |  
PDF [702 KB, uploaded 14 November 2018]
  |  

Abstract

Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong antioxidant and anticancer properties that is present in high quantity in a variety of berries, pomegranates, and dried fruits. The antitumor activity of EA has been mostly attributed to direct antiproliferative and apoptotic effects. Moreover, EA can inhibit tumour cell migration, extra-cellular matrix invasion and angiogenesis, all processes that are crucial for tumour infiltrative behaviour and the metastatic process. In addition, EA may increase tumour sensitivity to chemotherapy and radiotherapy. The aim of this review is to summarize the in vitro and in vivo experimental evidence supporting the anticancer activity of pure EA, its metabolites, and EA-containing fruit juice or extracts in a variety of solid tumour models. The EA oral administration as supportive therapy to standard chemotherapy has been recently evaluated in small clinical studies with colorectal or prostate cancer patients. Novel formulations with improved solubility and bioavailability are expected to fully develop the therapeutic potential of EA derivatives in the near future. View Full-Text
Keywords: polyphenolic compounds; colorectal cancer; breast cancer; prostate cancer; non-small cell lung cancer (NSCLC); melanoma; bladder cancer; ovarian cancer; metastases; angiogenesis polyphenolic compounds; colorectal cancer; breast cancer; prostate cancer; non-small cell lung cancer (NSCLC); melanoma; bladder cancer; ovarian cancer; metastases; angiogenesis
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ceci, C.; Lacal, P.M.; Tentori, L.; De Martino, M.G.; Miano, R.; Graziani, G. Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid. Nutrients 2018, 10, 1756.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top